drugset / Trial / NCT04296695

Biktarvy in Treatment-Naïve Late Presenters With HIV-1 Infection

NCT04296695

RandomizedParallel-groupOpen-labelTreatment

Summary

The efficacy and safety of Biktarvy in Treatment-Naïve Late Presenters with HIV-1 Infection

Timeline

Start
2021-07-14
Primary completion
2022-12-13
Completion
2025-06-06

Drugs

EvaluationDrugModalityDoseRoute
Subject B/F/TAF Unknown
Comparator EFV Unknown 400 mg
Comparator Lamivudine Other / unclassified 300 mg
Comparator TDF Unknown 300 mg